

***Fiscal Year 2020 Department of Defense Amyotrophic Lateral Sclerosis Research Program  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadlines
<p><b>Therapeutic Development Award</b></p> <p>Go to:</p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">W81XWH-20-ALSRP-TDA</a></p>	<p>Independent investigators at all levels</p>	<ul style="list-style-type: none"> <li>• <b>Pre-Application is required; Full Application submission is by invitation only</b></li> <li>• Supports preclinical secondary validation and IND-enabling studies of therapeutics for ALS.</li> <li>• Preliminary data are required, including efficacy in at least one ALS-relevant model system with a lead molecule/class of compounds.</li> <li>• <b>Biomarker development</b> and/or characterization (if not already validated), <u>in parallel to the main therapeutic effort</u>, is a critical component of the TDA proposal.</li> </ul>	<ul style="list-style-type: none"> <li>• Maximum funding of <b>\$1.0 million</b> for direct costs (plus indirect costs)</li> <li>• Maximum period of performance is <b>3 years</b></li> </ul>	<p><b>Pre-Application:</b> April 15, 2020 5:00 p.m. Eastern time</p> <p>Preproposal is required; application submission is by invitation only.</p> <p><b>Application:</b> July 30, 2020 11:59 p.m. Eastern Time</p>
<p><b>Therapeutic Idea Award</b></p> <p>Go to:</p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">W81XWH-20-ALSRP-TIA</a></p>	<p>Independent investigators at all levels</p>	<ul style="list-style-type: none"> <li>• <b>Pre-Application is required; Full Application submission is by invitation only</b></li> <li>• Supports hypothesis-driven preclinical therapeutic development.</li> <li>• Preliminary data are not required.</li> <li>• Projects focusing primarily on investigating ALS pathophysiology are outside the scope of this award mechanism.</li> <li>• Early Career Investigators are encouraged to apply.</li> <li>• <b>Therapeutic Relevant Biomarker Option:</b> Applications which include the development of biomarkers in parallel with the main therapeutic advancement effort, and that meet the criteria outlined in the Funding Opportunity Announcement, will qualify for a higher level of funding.</li> </ul>	<ul style="list-style-type: none"> <li>• Maximum funding of <b>\$500,000</b> for direct costs (plus indirect costs)</li> <li>• Maximum funding of <b>\$600,000</b> for direct costs plus indirect costs if applying for the Therapeutic Relevant Biomarker Option</li> <li>• Maximum period of performance is <b>2 years</b></li> </ul>	<p><b>Pre-Application:</b> April 15, 2020 5:00 p.m. Eastern time</p> <p>Preproposal is required; application submission is by invitation only.</p> <p><b>Application:</b> July 30, 2020 11:59 p.m. Eastern Time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadlines
<p><b>Clinical Development Award</b></p> <p>Go to:</p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">W81XWH-20-ALSRP-CDA</a></p>	<p>Independent investigators at all levels</p>	<ul style="list-style-type: none"> <li>• <b>Pre-application is required; full application submission is by invitation only.</b></li> <li>• Supports leveraging of human-based ALS resources through correlative clinical research.</li> <li>• Early Career Investigators and/or Early Career Physician Scientists are encouraged to apply.</li> <li>• Types of efforts that will be supported include:</li> <li>• Using human subject-based resources to better define subtypes, predict therapeutic response, or assess prognosis</li> <li>• Correlating clinical trial-related biosamples, imaging, or epidemiological data with clinical outcomes</li> <li>• Adding a companion aim/goal to an anticipated/ongoing clinical trial, not otherwise supported by the trial</li> <li>• Studies to evaluate optimizing components of current ALS clinical care</li> </ul>	<ul style="list-style-type: none"> <li>• Maximum funding of <b>\$300,000</b> for direct costs (plus indirect costs)</li> <li>• Maximum period of performance is <b>2 years</b></li> </ul>	<p><b>Pre-Application:</b> April 15, 2020 5:00 p.m. Eastern time</p> <p>Preproposal is required; application submission is by invitation only.</p> <p><b>Application:</b> July 30, 2020 11:59 p.m. Eastern Time</p>